These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

461 related articles for article (PubMed ID: 16007238)

  • 1. Piracetam: a review of pharmacological properties and clinical uses.
    Winblad B
    CNS Drug Rev; 2005; 11(2):169-82. PubMed ID: 16007238
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Piracetam--an old drug with novel properties?
    Winnicka K; Tomasiak M; Bielawska A
    Acta Pol Pharm; 2005; 62(5):405-9. PubMed ID: 16459490
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of piracetam on ataxia: clinical observations in a group of autosomal dominant cerebellar ataxia patients.
    Ince Gunal D; Agan K; Afsar N; Borucu D; Us O
    J Clin Pharm Ther; 2008 Apr; 33(2):175-8. PubMed ID: 18315783
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Effect of piracetam on urea-induced myoclonus in rats].
    Nanri M; Yamamoto A; Matsuura N
    Nihon Shinkei Seishin Yakurigaku Zasshi; 2000 May; 20(2):45-50. PubMed ID: 11062861
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [A pharmacological profile of piracetam (Myocalm), a drug for myoclonus].
    Tajima K; Nanri M
    Nihon Yakurigaku Zasshi; 2000 Oct; 116(4):209-14. PubMed ID: 11084917
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Piracetam in the treatment of cortical myoclonus.
    Genton P; Guerrini R; Remy C
    Pharmacopsychiatry; 1999 Mar; 32 Suppl 1():49-53. PubMed ID: 10338109
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Controlled pilot study of piracetam for pediatric opsoclonus-myoclonus.
    Pranzatelli MR; Tate ED; Galvan I; Wheeler A
    Clin Neuropharmacol; 2001; 24(6):352-7. PubMed ID: 11801811
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Piracetam and piracetam-like drugs: from basic science to novel clinical applications to CNS disorders.
    Malykh AG; Sadaie MR
    Drugs; 2010 Feb; 70(3):287-312. PubMed ID: 20166767
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Piracetam in the treatment of myoclonus: an overview.
    Van Vleymen B; Van Zandijcke M
    Acta Neurol Belg; 1996 Dec; 96(4):270-80. PubMed ID: 9008776
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Piracetam is useful in the treatment of children with sickle cell disease.
    el-Hazmi MA; Warsy AS; al-Fawaz I; Opawoye AO; Taleb HA; Howsawi Z; Mohamed AA; Aly AW; Refai S; Sugathan PS; Rab AS; Ahmed HB; Abulaban M; Abdulkader AM; Farid M
    Acta Haematol; 1996; 96(4):221-6. PubMed ID: 8922488
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interaction between psychological and pharmacological treatment in cognitive impairment.
    Deberdt W
    Life Sci; 1994; 55(25-26):2057-66. PubMed ID: 7997065
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Piracetam: novelty in a unique mode of action.
    Müller WE; Eckert GP; Eckert A
    Pharmacopsychiatry; 1999 Mar; 32 Suppl 1():2-9. PubMed ID: 10338102
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Piracetam. An overview of its pharmacological properties and a review of its therapeutic use in senile cognitive disorders.
    Vernon MW; Sorkin EM
    Drugs Aging; 1991 Jan; 1(1):17-35. PubMed ID: 1794001
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Treatment and long-term follow-up of post-anoxic myoclonus].
    Janszky J; Holló A; Halász P
    Orv Hetil; 2001 Sep; 142(38):2091-3. PubMed ID: 11697066
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Comparative evaluation of the neuroprotective activity of phenotropil and piracetam in laboratory animals with experimental cerebral ischemia].
    Tiurenkov IN; Bagmetov MN; Epishina VV
    Eksp Klin Farmakol; 2007; 70(2):24-9. PubMed ID: 17523446
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical trial of piracetam in patients with myoclonus: nationwide multiinstitution study in Japan. The Myoclonus/Piracetam Study Group.
    Ikeda A; Shibasaki H; Tashiro K; Mizuno Y; Kimura J
    Mov Disord; 1996 Nov; 11(6):691-700. PubMed ID: 8914096
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Erythrocyte - endothelial cell adherence in sickle cell disease, diabetes mellitus, and falciparum malaria: adverse effects reversed with piracetam.
    Nalbandian RM; Henry RL; Fleischman JA; Burek L; Williams G; O'Donnell FE; Diglio CA; Collier BD; Reeser FH
    Med Hypotheses; 1982 Feb; 8(2):155-62. PubMed ID: 7045599
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical efficacy of piracetam in cognitive impairment: a meta-analysis.
    Waegemans T; Wilsher CR; Danniau A; Ferris SH; Kurz A; Winblad B
    Dement Geriatr Cogn Disord; 2002; 13(4):217-24. PubMed ID: 12006732
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Piracetam improves cognitive deficits caused by chronic cerebral hypoperfusion in rats.
    He Z; Liao Y; Zheng M; Zeng FD; Guo LJ
    Cell Mol Neurobiol; 2008 Jun; 28(4):613-27. PubMed ID: 17710536
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Piracetam and levetiracetam: close structural similarities but different pharmacological and clinical profiles.
    Genton P; Van Vleymen B
    Epileptic Disord; 2000 Jun; 2(2):99-105. PubMed ID: 10954241
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.